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IN EARLIER TIMES, information about en-
vironmental carcinogenesis in man depended
on chance clinical observations, followed
(usually much later) by experimental identi-
fication of the incriminating agents (see
Hueper & Conway, 1964). This is now being
replaced (a) by more systematic epidemio-
logical surveys, and (b) by the introduction
ofindependent routine carcinogenicity testing
of all kinds of substances to which man
might be exposed. We are still, in fact, at a
transition stage in this change-over.
The new approach was prompted by the
growing realization that the environment
played a far greater role in human cancer
development than had previously been sup-
posed, with industrial exposure constituting
a relatively small proportion of the overall
carcinogenic risk (see WHO, 1964; Higginson
& Muir, 1976; Doll, 1977). The real purpose
of the new approach, especially that of rout-
ine testing, was to anticipate knowledge of
carcinogenic action, and thereby to facilitate
the introduction of preventive measures
10-30 years earlier than would be possible if
one waited each time until clinical evidence
of an association became available.
But the change in approach raised 3 im-
portant questions: (1) how to acquire such
information on a scale hardly possible by
standard animal testing; (2) how to establish
the accuracy of the results obtained by the
new (alternative) testing methods; and (3)
how to interpret the information thus
acquired in terms of human risks.
Mutagenicity tests (Ames et al., 1975) and
other short-term methods of assay (see
Goldenberg, 1974; Bridges, 1976; Purchase
et al., 1978) are designed to overcome the
first of these problems, namely, to cope with
large-scale testing by relatively simple
methods capable of yielding quick results.
The accuracy is checked by comparing the
results with available data from animal
testing (McCann et al., 1975; Bartsch, 1976;
Ashby & Styles, 1978) but this is really beg-
ging the question, since meaningful compari-
sons should be with human responses, which
are naturally not yet available for com-
pounds newly introduced in the environment.
This brings me to the third problem-that of
interpretation in terms of human risks-
which goes far beyond the question of accuracy
of results.
Other participants of this symposium are
dealing with technical aspects of laboratory
testing, with the evaluation of false positives
and false negatives, and with results of
epidemiological surveys. I shall confine
myself to discussing some basic problems of
carcinogenesis that have a bearing on the
assessment of human risks.
How tempting it is to look upon carcino-
genesis as a clearly defined process that can
be expressed in absolute terms and measured
quantitatively. This is, after all, implied when
we distinguish, in anuncompromising fashion,
between carcinogenic and noncarcinogenic
compounds, and when we grade carcinogenic
action as potent, moderate, or weak. Yet half
a century of research into the biological and
biochemical mechanisms of action, relating
to physical, chemical, hormonal and viral
carcinogenesis, and with evidence of genetic
differences in response and of a wide range of
cocarcinogenic and anticarcinogenic in-
fluences (see Berenblum, 1974) makes it
abundantly clear that such an oversimplified
concept of carcinogenesis can only lead one
astray in trying to assess the risks for man,
as a guide to cancer prevention.
In the past, the distinction between car-
cinogenic and noncarcinogenic compounds
was based on experimental findings that the
former did produce tumours when adminis-
tered to animals, while the latter did not.
This is now being superseded by determining
whether the compound is or is not mutagenic.
The criteria in the case of animal testing
may be described as direct evidence, those
used in mutagenicity testing as indirect
evidence. There are, however, inherent limita-
tions in both cases and, what is more, these
limitations are different between the two
systems of evaluation.
I should like first to consider some of the
limitations of animal testing, as a method of
determining carcinogenesis and of estimating
the potency of a compound.
When the various methyl derivatives of
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benzanthracene were originally tested, at
do,3es of 1-5 mg, the 7-methyl derivative
proved to be carcinogenic while the I-, 2-,
3-, and4-methyl derivatives were found to be
inactive. (These refer to testing by s.c.
injection. It is difficult to estimate the amount
absorbed after skinpainting.) However, when
acetylaminofluorene and aminoazo com-
pounds were tested for careinogenesis, these
were administered at cumulative doses of
100 mg or more. Imagine what the results
might have been if the "non-carcinogenic"
benzanthracene derivatives had been tested
at dose levels of 100 mg and if acetylamino-
fluorene or the aminoazo compounds had
been tested at 1-5 mg dose levels!
As for difficulties in quantitating carcino-
genic potency, benzpyrene is known to pro-
duce tumours in mice and rats at a dose as
low as 2 pg or even less, whereas g-naphthyl
amine has to be administered to dogs at a
cumulative dose of at least 20g to produce
tumours. This is a difference of 7 orders of
magnitude! Does this mean that benzpyrene
is 10,000,000 times more potent that g-
naphthylamine? Or, allowing for the respec-
tive differences in body weight between
laboratory rodents anddogs, that benzpyrene
is many thousand times more potent? If so,
how can one account for the fact that workers
in the synthetic dye industry, exposed to
9-naphthylamine, had a risk close to 100%
ofdeveloping tumours oftheurinary bladder,
whereas most of us, exposed to relatively
large amounts of benzpyrene in our daily lives, do not develop cancer with anything
approaching that degree offrequenc3,?
Grading carcinogenic potency does not, of
course, depend solely on ininimal dose re-
quirements for tumour induction. There are
also other parameters, such as percentage of
tumour yield under standard conditions of
dosage,numberoftumourspertreatedanimal,
average latent period ofcareinogenesis, types oftumourproduced, differences inspecies and
strain responses, etc. Anyone familiar with
carcinogenicity studies in animals knows that
these are not interchangeable criteria or
related parameters.
Particular importance is attached to
differences in species response in trying to
extrapolate results from animal testing to
carcinogenicity risks for man. There is
already ample evidence from metabolic
studies to account for at least some of the
variations in species response (Brookes, 1975;
Miller, 1978; Irving, 1979). Since most carci-
nogens have to be converted into active
metabolites in the body before being able to
react with cell constituents to cause neoplas-
tic transformation, absence of the necessary
enzyme system in the particular species can
readily account for failure to respond to the
parent compound.
Other complications arise from differences
in organ response according to the class of
compound to which the carcinogen belongs.
Broadlyspeaking, carcinogens can be divided
into 3 main categories: (i) those that are
potentially carcinogenic for all tissues-e.g.,
the polycyclic aromatic hydrocarbons: (ii)
those that are carcinogenic for a strictly
limited number oftarget organs-e.g., acety-
laminofluorene, urethane and the nitro-
samines; and (iii) those that are essentially
single-organ carcinogens-e.g., g-naphthy-
lamine, aminoazo compounds, ethionine, and
aflatoxin. To compare their respective car-
cinogenic potencies on a quantitative basis
would obviously be meaningless. No one
would seriously suggest, for instance, that
acetylaminofluorene is about 12 times as
potent as aflatoxin, because it is carcinogenic
for a dozen or so organs, whilst aflatoxin is
mainly carcinogenic for the liver.
Animal testing can at least distinguish
between the 3 classes of compounds, thus
enabling one to specify which organs are
likely to be affected in man. In vitro testing
for mutagenesis can only provide general
information about potential carcinogenicity,
witliout indicating which organs or tissues
would respond in vivo.
This brings me to a more crucial point-
the fact that carcinogenesis is not a single,
all-or-none process, but comprises a series of
consecutive events, of which two are clearly
identifiable: an initial, rapid, irreversible
change in the cell, supposedly brought about
by a mutation, and known as the initiatinri
phase, followed by a gradual process of
94activation" of the mutated cell or its pro-
geny, during the long latent period-almost
certainly epigenetic in mode of action, and
known as thepromotingphase (seeBerenblum,
1974; Stenbiick et al., 1974; Van Duuren,
1976; Slaga et al., 1978; Sivak, 1979).
.- This "two-stage theory of carcinogenesis",
including the concept that neoplastically
transformed cells are capable ofpersisting in
a "dormant" state, was once thought to
relate niainly to skin (in which it was firstBRITISH ASSOCIATION FOR CANCER RESEARCH
identified and carefully analysed) and was
for long considered to be of limited, academic
interest. It is now known to apply to many
other tissues in the body and is strongly sus-
pected of operating in man as well.
One of the reasons for the long delay in
accepting the initiation-promotion principle
in human carcinogenesis was, surprisingly
enough, reluctance to acknowledge that can-
cer cells in man could remain dormant, until
"awakened" by some appropriate stimulus.
I say "surprisingly", because functional
dormancy is, after all, one of the basic
principles ofontogenesis. All cells in the body
are known to carry the full complement of
genes, derived from the fertilized ovum, but
most of the genes remain repressed through-
out life, only a few being allowed to express
themselves, in any particular organ, per-
mitting tissue differentiation. If normal genes
can remain functionally dormant, why not
"tumour" genes as well?
How promoting action-i.e., the "awaken-
ing" process-operates, is still unclear. Even
less is known about the way promoting action
eventually becomes self-perpetuating. These
are problems of considerable theoretical
importance with obvious practical implica-
tions, and intensive efforts are being made in
many laboratories to try to find the answers
(Slaga et al., 1978).
Meanwhile, attention may be drawn to the
relevance of the initiation-promotion prin-
ciple to human carcinogenesis, from 3
different viewpoints:
1. The Ames test (or indeed any form of
mutagenicity testing system) canonlyidentify
the initiating phase of carcinogenesis, and
cannot therefore recognize pure promoting
agents, potentially operative in man.
2. Initiating action alone (i.e., without sub-
sequent promoting action) is generally in-
effective in inducing tumours. Identification
of promoting agents may thus have more
relevance to human carcinogenesis than
identification of initiating agents. This is
another way of saying that the admittedly
important and revealing evidence of muta-
genicity may not be the most crucial infor-
mation in relation to carcinogenic risks for
man.
3. The exclusion of "complete" carcinogens
from man's environment may have only
limited scope for cancer prevention, whereas
exclusion of independent promoting action
may prove to be as important, ifnot more so.
This presents us with the most challenging
problem of all-how to devise practical
methods of identifying promoting agents.
From what we know at present, it is hard to
visualize one single testing system for all
potential promoting agents by animal testing,
let alone by any short-term technique. A few
experimental models for systemic promoting
action in animals have been devised in recent
years, but these would seem to be too com-
plicated for routine purposes.
I might refer, in this connection, to our
own current attempts at transplacental 2-
stage carcinogenesis in animals, with a
"broad-spectrum" initiator administered to
the pregnant mother and the potential
promoter to the offspring after birth (Armuth
& Berenblum, 1979).
This symposium is perhaps not the appro-
priate occasion to enlarge on the different
methods of cancer prevention, except to refer
briefly to the 4 hypothetical points of attack
(Berenblum, 1974): (i) by eliminating "com-
plete" carcinogens from the environment (the
conventional method of cancer prevention
in man); (ii) by eliminating initiators from
man's environment (based on results of
mutagenicity tests); (iii) by eliminating the
various promoting factors during the long
latent period of carcinogenesis (for which no
satisfactory testing systems exist at present);
and (iv) by interfering with the carcinogenic
process, as distinct from eliminating the
incriminating factors (a possibility still at the
experimental stage of enquiry (see Watten-
berg, 1978) though the results are sufficiently
encouraging to offer reasonable prospects of
future application).
To conclude, we seem to have come a long
way from when the conflict between chemical
specificity and chemical diversity of carcino-
genic agents dominated our thinking in trying
to understand how carcinogens act. The
common factor among the diverse agents can
now be traced to similarities in reactivity of
their metabolic products, rather than to
physico-chemical or structural properties of
the parent compounds. At a more practical
level, epidemiological studies have brought to
light a great variety of behavioural, social,
dietetic, occupational, and other factors in
man's mode of life, which influence his
chances of developing cancer (some acting
additively, and others apparently as pro-
moting factors); while chemical analysis of
air and water pollutants, food contaminants,
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etc., have added to our knowledge of poten-
tial carcinogens in the environment.
Naturally, the more information we can
gather about specific carcinogens in our
environment and the more we discover about
the various kinds oftumour promotion opera-
ting in man, the better our chances will be
in reducing the prevailing cancer incidence.
But in the final analysis carcinogenesis is a
biological problem, and only by taking
cognizance of the biological process, with all
its complications, can a rational procedure be
formulated in trying to eradicate the disease.
Practical applications often call for a prag-
matic approach, but a proper understanding
of the basic principles is necessary to avoid
drawing false conclusions and to minimize
the chances of following up false leads.
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